Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

A new study suggests Paxlovid may not reduce the risk of covid-19 hospitalizations and all-cause deaths in vaccinated adults ...

That’s very different from the results that Paxlovid’s maker, Pfizer, first reported in 2022. In that study, Pfizer found that the drug reduced hospitalizations and deaths from COVID-19 by 89% ...

Pfizer has revealed what it will charge for a five-day course of its oral antiviral Paxlovid for COVID-19 when it starts to see it on the commercial market later this year. The drugmaker has set a ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Investor enthusiasm hit a fever pitch following the 2024 election, but took a punch to the gut recently. Market indexes have ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. The study questions the assumption that Paxlovid's ...

“I think that needs to be part of the conversation.” A spokesperson for Pfizer, which makes Paxlovid, said the company stands by its effectiveness for patients at high risk for severe illness.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...